Incidence of cancer in a cohort of patients with primary Sjögren's syndrome
Identifieur interne : 001014 ( Istex/Corpus ); précédent : 001013; suivant : 001015Incidence of cancer in a cohort of patients with primary Sjögren's syndrome
Auteurs : M. N. Lazarus ; D. Robinson ; V. Mak ; H. M Ller ; D. A. IsenbergSource :
- Rheumatology [ 1462-0324 ] ; 2006.
Abstract
Objective. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England. Methods. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers. Results. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6). Conclusion. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.
Url:
DOI: 10.1093/rheumatology/kei281
Links to Exploration step
ISTEX:CA2B6C7023C48C58447B90FC11749151572EE9B6Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title><author><name sortKey="Lazarus, M N" sort="Lazarus, M N" uniqKey="Lazarus M" first="M. N." last="Lazarus">M. N. Lazarus</name><affiliation><mods:affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</mods:affiliation></affiliation></author><author><name sortKey="Robinson, D" sort="Robinson, D" uniqKey="Robinson D" first="D." last="Robinson">D. Robinson</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="Mak, V" sort="Mak, V" uniqKey="Mak V" first="V." last="Mak">V. Mak</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="M Ller, H" sort="M Ller, H" uniqKey="M Ller H" first="H." last="M Ller">H. M Ller</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="Isenberg, D A" sort="Isenberg, D A" uniqKey="Isenberg D" first="D. A." last="Isenberg">D. A. Isenberg</name><affiliation><mods:affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CA2B6C7023C48C58447B90FC11749151572EE9B6</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1093/rheumatology/kei281</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001014</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001014</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title><author><name sortKey="Lazarus, M N" sort="Lazarus, M N" uniqKey="Lazarus M" first="M. N." last="Lazarus">M. N. Lazarus</name><affiliation><mods:affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</mods:affiliation></affiliation></author><author><name sortKey="Robinson, D" sort="Robinson, D" uniqKey="Robinson D" first="D." last="Robinson">D. Robinson</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="Mak, V" sort="Mak, V" uniqKey="Mak V" first="V." last="Mak">V. Mak</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="M Ller, H" sort="M Ller, H" uniqKey="M Ller H" first="H." last="M Ller">H. M Ller</name><affiliation><mods:affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</mods:affiliation></affiliation></author><author><name sortKey="Isenberg, D A" sort="Isenberg, D A" uniqKey="Isenberg D" first="D. A." last="Isenberg">D. A. Isenberg</name><affiliation><mods:affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Rheumatology</title><title level="j" type="abbrev">Rheumatology</title><idno type="ISSN">1462-0324</idno><idno type="eISSN">1462-0332</idno><imprint><publisher>Oxford University Press</publisher><date type="e-published" when="2006-02-20">2006</date><date when="2006-08">2006</date><biblScope unit="vol">45</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1012">1012</biblScope><biblScope unit="page" to="1015">1015</biblScope></imprint><idno type="ISSN">1462-0324</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England. Methods. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers. Results. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6). Conclusion. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.</div></front></TEI><istex><corpusName>oup</corpusName><keywords><teeft><json:string>lymphoma</json:string><json:string>primary syndrome</json:string><json:string>general population</json:string><json:string>adenocarcinoma</json:string><json:string>tumour</json:string><json:string>syndrome</json:string><json:string>thames cancer registry</json:string><json:string>additional cancer</json:string><json:string>arthritis rheum</json:string><json:string>malignancy</json:string><json:string>malt</json:string><json:string>rheum</json:string><json:string>subsequent cancer</json:string><json:string>greater risk</json:string><json:string>carcinoma</json:string><json:string>skin cancer</json:string><json:string>malignant cancer</json:string><json:string>other cancer</json:string><json:string>malignant lymphoma</json:string><json:string>standardized incidence ratio</json:string><json:string>systemic autoimmune disease</json:string><json:string>separate analysis</json:string><json:string>main analysis</json:string><json:string>cancer subsequent</json:string><json:string>previous study</json:string><json:string>university college hospital</json:string><json:string>excess mortality</json:string><json:string>defective repair</json:string><json:string>censoring date</json:string><json:string>semin arthritis rheum</json:string><json:string>lymphoproliferative disorder</json:string><json:string>cancer diagnosis</json:string><json:string>lymphoma development</json:string></teeft></keywords><author><json:item><name>M. N. Lazarus</name><affiliations><json:string>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</json:string></affiliations></json:item><json:item><name>D. Robinson</name><affiliations><json:string>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</json:string></affiliations></json:item><json:item><name>V. Mak</name><affiliations><json:string>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</json:string></affiliations></json:item><json:item><name>H. Møller</name><affiliations><json:string>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</json:string></affiliations></json:item><json:item><name>D. A. Isenberg</name><affiliations><json:string>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Sjögren's syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cancer</value></json:item></subject><arkIstex>ark:/67375/HXZ-4GZSGV12-V</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Objective. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England. Methods. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers. Results. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6). Conclusion. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.</abstract><qualityIndicators><score>6.297</score><pdfWordCount>2630</pdfWordCount><pdfCharCount>17028</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>595 x 791 pts</pdfPageSize><pdfWordsPerPage>658</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>275</abstractWordCount><abstractCharCount>1828</abstractCharCount><keywordCount>2</keywordCount></qualityIndicators><title>Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title><pmid><json:string>16490754</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Rheumatology</title><language><json:string>unknown</json:string></language><issn><json:string>1462-0324</json:string></issn><eissn><json:string>1462-0332</json:string></eissn><publisherId><json:string>brheum</json:string></publisherId><volume>45</volume><issue>8</issue><pages><first>1012</first><last>1015</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1963</json:string><json:string>1979</json:string><json:string>1993</json:string><json:string>2006-02-20</json:string></date><geogName></geogName><orgName><json:string>Society for Rheumatology</json:string><json:string>Department of Medicine, University College London, Arthur Stanley House</json:string><json:string>Oxford University</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>D. Robinson</json:string><json:string>M. N. Lazarus</json:string><json:string>Observed</json:string><json:string>V. Mak</json:string><json:string>H. Møller</json:string></persName><placeName></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[23]</json:string><json:string>M. N. Lazarus et al. 1014</json:string><json:string>[18]</json:string><json:string>[17]</json:string><json:string>[1]</json:string><json:string>[6, 8]</json:string><json:string>[16]</json:string><json:string>[5]</json:string><json:string>[14]</json:string><json:string>[13]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/HXZ-4GZSGV12-V</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - arthritis & rheumatology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1093/rheumatology/kei281</json:string></doi><id>CA2B6C7023C48C58447B90FC11749151572EE9B6</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><licence>© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</licence></availability><date type="e-published" when="2006-02-20">2006</date><date when="2006-08">2006</date><date type="Copyright" when="2006">2006</date></publicationStmt><notesStmt><note type="content-type" source="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title><author xml:id="author-0000"><persName><surname>Lazarus</surname><forename type="first">M. N.</forename></persName><affiliation><orgName type="institution">Centre for Rheumatology</orgName><address><addrLine>Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation><affiliation role="corresp">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</affiliation></author><author xml:id="author-0001"><persName><surname>Robinson</surname><forename type="first">D.</forename></persName><affiliation><orgName type="institution">Centre for Rheumatology</orgName><address><addrLine>Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation><affiliation role="corresp">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</affiliation></author><author xml:id="author-0002"><persName><surname>Mak</surname><forename type="first">V.</forename></persName><affiliation><orgName type="institution">Centre for Rheumatology</orgName><address><addrLine>Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation><affiliation role="corresp">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</affiliation></author><author xml:id="author-0003"><persName><surname>Møller</surname><forename type="first">H.</forename></persName><affiliation><orgName type="institution">Centre for Rheumatology</orgName><address><addrLine>Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation><affiliation role="corresp">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</affiliation></author><author xml:id="author-0004"><persName><surname>Isenberg</surname><forename type="first">D. A.</forename></persName><affiliation><orgName type="institution">Centre for Rheumatology</orgName><address><addrLine>Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK</addrLine><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation><affiliation role="corresp">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</affiliation></author><idno type="istex">CA2B6C7023C48C58447B90FC11749151572EE9B6</idno><idno type="ark">ark:/67375/HXZ-4GZSGV12-V</idno><idno type="other">kei281</idno><idno type="DOI">10.1093/rheumatology/kei281</idno></analytic><monogr><title level="j" type="main">Rheumatology</title><title level="j" type="abbrev">Rheumatology</title><idno type="hwp">rheumatology</idno><idno type="nlm-ta">Rheumatology (Oxford)</idno><idno type="publisher-id">brheum</idno><idno type="pISSN">1462-0324</idno><idno type="eISSN">1462-0332</idno><imprint><publisher>Oxford University Press</publisher><date type="e-published" when="2006-02-20">2006</date><date when="2006-08">2006</date><biblScope unit="vol">45</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1012">1012</biblScope><biblScope unit="page" to="1015">1015</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en"><p><hi rend="italic">Objective</hi>. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England.</p><p><hi rend="italic">Methods</hi>. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers.</p><p><hi rend="italic">Results</hi>. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6).</p><p><hi rend="italic">Conclusion</hi>. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.</p></abstract><textClass ana="subject"><keywords scheme="heading"><term>CLINICAL</term></keywords></textClass><textClass ana="keyword"><keywords scheme="KWD" xml:lang="en"><term>Sjögren's syndrome</term><term>Cancer</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">rheumatology</journal-id><journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>
<journal-id journal-id-type="publisher-id">brheum</journal-id><journal-title>Rheumatology</journal-title><abbrev-journal-title abbrev-type="publisher">Rheumatology</abbrev-journal-title><issn pub-type="ppub">1462-0324</issn><issn pub-type="epub">1462-0332</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">kei281</article-id><article-id pub-id-type="doi">10.1093/rheumatology/kei281</article-id><article-categories><subj-group subj-group-type="heading"><subject>CLINICAL</subject></subj-group></article-categories><title-group><article-title>Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</article-title></title-group><contrib-group>
<contrib contrib-type="author"><name><surname>Lazarus</surname><given-names>M. N.</given-names></name>
</contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>D.</given-names></name>
<xref rid="AFF1">
<sup>1</sup>
</xref>
</contrib><contrib contrib-type="author"><name><surname>Mak</surname><given-names>V.</given-names></name>
<xref rid="AFF1">
<sup>1</sup>
</xref>
</contrib><contrib contrib-type="author"><name><surname>Møller</surname><given-names>H.</given-names></name>
<xref rid="AFF1">
<sup>1</sup>
</xref>
</contrib><contrib contrib-type="author"><name><surname>Isenberg</surname><given-names>D. A.</given-names></name>
</contrib><aff>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and <target target-type="aff" id="AFF1"></target><label>1</label>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</aff></contrib-group><author-notes><corresp>Correspondence to: M. N. Lazarus, E-mail: <ext-link xlink:href="marklazarus@msn.com" ext-link-type="email">marklazarus@msn.com</ext-link>; or D. A. Isenberg, E-mail: <ext-link xlink:href="d.isenberg@ucl.ac.uk" ext-link-type="email">d.isenberg@ucl.ac.uk</ext-link></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>2</month><year>2006</year></pub-date><pub-date pub-type="ppub"><month>August</month><year>2006</year></pub-date><volume>45</volume><issue>8</issue><fpage>1012</fpage><lpage>1015</lpage><history><date date-type="received"><day>12</day><month>8</month><year>2005</year></date><date date-type="rev-recd"><day>29</day><month>11</month><year>2005</year></date></history><permissions><copyright-statement>© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</copyright-statement><copyright-year>2006</copyright-year></permissions><abstract xml:lang="en">
<p><italic>Objective</italic>. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England.</p>
<p><italic>Methods</italic>. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers.</p>
<p><italic>Results</italic>. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6).</p>
<p><italic>Conclusion</italic>. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.</p>
</abstract><kwd-group kwd-group-type="KWD" xml:lang="en">
<kwd>Sjögren's syndrome</kwd>
<kwd>Cancer</kwd>
</kwd-group><custom-meta-wrap><custom-meta><meta-name>hwp-legacy-fpage</meta-name><meta-value>1012</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2006</meta-value></custom-meta><custom-meta><meta-name>hwp-legacy-dochead</meta-name><meta-value>PAPER</meta-value></custom-meta></custom-meta-wrap></article-meta></front>
</article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Incidence of cancer in a cohort of patients with primary Sjögren's syndrome</title></titleInfo><name type="personal"><namePart type="given">M. N.</namePart><namePart type="family">Lazarus</namePart><affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">Robinson</namePart><affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Mak</namePart><affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Møller</namePart><affiliation>King's College London, Thames Cancer Registry, 1st Floor Capital House, 42 Weston Street, London SE1 3QD, UK.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D. A.</namePart><namePart type="family">Isenberg</namePart><affiliation>Centre for Rheumatology, Department of Medicine, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ and</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">2006-08</dateIssued><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Objective. To compare the incidence of subsequent cancers in a cohort of patients with primary Sjögren's syndrome (pSS) with that of the general population in the same region of England. Methods. A retrospective analysis was carried out on 112 patients who had attended the out-patients department at University College Hospital, London, from 1979 onwards. Patients were followed up from diagnosis of pSS to diagnosis of first subsequent cancer, death, loss to follow-up or 31 December 2003 (the censoring date) to determine the person-years at risk for each individual. The expected numbers of subsequent cancers were calculated from sex-/age-/period-specific rates for the general population of southeast England, derived from registrations at the Thames Cancer Registry. Standardized incidence ratios (SIRs) were then calculated as the ratio of observed to expected numbers of cancers, along with 95% confidence intervals (CIs). Separate analyses were performed for all malignant cancers combined, lymphomas and non-lymphoid cancers. Results. Among the 112 patients with pSS, 25 developed cancer (either before or after development of pSS), with lymphoma occurring in 11 cases. Nine patients had two cancers. There was a significantly elevated incidence of lymphomas in pSS patients compared with the general population (SIR 37.5, 95% CI 20.7–67.6). For non-lymphoid cancer, the observed increase in incidence was small and not statistically significant (SIR 1.5, 95% CI 0.9–2.6). Conclusion. This study confirms that there is an increased incidence of lymphoma in patients with pSS. An increase in the incidence of other cancers was not proven but the observation that some patients developed more than one cancer raises the possibility that there may be a subgroup of patients who are at greater risk of developing cancer.</abstract><note type="author-notes">Correspondence to: M. N. Lazarus, E-mail: marklazarus@msn.com; or D. A. Isenberg, E-mail: d.isenberg@ucl.ac.uk</note><subject lang="en"><genre>KWD</genre><topic>Sjögren's syndrome</topic><topic>Cancer</topic></subject><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><titleInfo type="abbreviated"><title>Rheumatology</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1462-0324</identifier><identifier type="eISSN">1462-0332</identifier><identifier type="PublisherID">brheum</identifier><identifier type="PublisherID-hwp">rheumatology</identifier><identifier type="PublisherID-nlm-ta">Rheumatology (Oxford)</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1012</start><end>1015</end></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB1"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><note>Talbot JH. Acute dermatomyositis-polymyositis and malignancy. Semin Arthritis Rheum 1977;6:305–60.</note><part><date>1977</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>305</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB2"><titleInfo><title>J Rheumatol</title></titleInfo><note>Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300–3.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1300</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB3"><titleInfo><title>Ann Rheum Dis</title></titleInfo><note>Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993;52:531–3.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>531</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB4"><titleInfo><title>Arthritis Rheum</title></titleInfo><note>Bernatsky S, Boivin JF, Jospeh L et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>1481</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB5"><titleInfo><title>Trans Assoc Am Physicians</title></titleInfo><note>Bunim JJ, Talal N. Development of malignant lymphoma in the course of Sjögren's syndrome. Trans Assoc Am Physicians 1963;76:45–56.</note><part><date>1963</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>45</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB6"><titleInfo><title>Ann Intern Med</title></titleInfo><note>Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888–92.</note><part><date>1978</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>888</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB7"><titleInfo><title>Scand J Rheumatol</title></titleInfo><note>Zuffery P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren's syndrome and malignant lymphoma. Scand J Rheumatol 1995;24:342–5.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>342</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB8"><titleInfo><title>J Rheumatol</title></titleInfo><note>Valesini G, Priori R, Bavoillot D et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol 1997;24:2376–80.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>2376</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB9"><titleInfo><title>J Clin Gastroenterol</title></titleInfo><note>Nagayama Y, Fujisawa A, Furutani A, Otsuki T, Yamabe H. Carcinoma of the sigmoid colon associated with Sjögren's syndrome. J Clin Gastroenterol 1993;17:268–9.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>268</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB10"><titleInfo><title>Scand J Rheumatol</title></titleInfo><note>Ota T, Wake A, Eto S, Kobayashi T. Sjögren's syndrome terminating with multiple myeloma. Scand J Rheumatol 1995;24:316–8.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>316</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB11"><titleInfo><title>Respirology</title></titleInfo><note>Takabatake N, Sayama T, Shida K, Matsuda M, Nakamura H, Tomoike H. Lung adenocarcinoma in lymphocytic interstitial pneumonitis associated with primary Sjögren's syndrome. Respirology 1999;4:181–4.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>181</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB12"><titleInfo><title>J Rheumatol</title></titleInfo><note>Molad Y, Okon E, Stark P, Prokocimer M. Sjögren's syndrome associated T cell large granular lymphocyte leukaemia: a possible common etiopathogenesis. J Rheumatol 2001;28:2551–2.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2551</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB13"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><note>Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998;28:80–7.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>80</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB14"><titleInfo><title>Arthritis Rheum</title></titleInfo><note>Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjögren's syndrome. Result of a prospective, concerted action supported by the European community. Arthritis Rheum 1993;36:340–8.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>340</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB15"><titleInfo><title>Arthritis Rheum</title></titleInfo><note>Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741–7.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>741</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB16"><titleInfo><title>Arthritis Rheum</title></titleInfo><note>Theander E, Manthorpe R, Jacobsson LTH. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262–9.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>1262</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB17"><titleInfo><title>Arthritis Rheum</title></titleInfo><note>Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's syndrome. Arthritis Rheum 1999;42:1765–72.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1765</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB18"><titleInfo><title>Ann Rheum Dis</title></titleInfo><note>Guo K, Major G, Foster H et al. Defective repair of O6-methylguanine-DNA in primary Sjögren's syndrome patients predisposed to lymphoma. Ann Rheum Dis 1995;54:229–32.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>229</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB19"><titleInfo><title>J Autoimmun</title></titleInfo><note>Fox RI, Saito I, Chan EK et al. Viral genomes in lymphomas of patients with Sjögren's syndrome. J Autoimmun 1989;2:449–55.</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>449</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB20"><titleInfo><title>J Rheumatol</title></titleInfo><note>Fox RI, Luppi M, Kang HI, Ablshi D, Josephs S. Detection of high levels of human herpes virus-6 DNA in a lymphoma of a patient with Sjögren's syndrome. J Rheumatol 1993;20:764–5.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>764</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB21"><titleInfo><title>J Oral Pathol Med</title></titleInfo><note>Klussmann JP, Wagner M, Guntinas-Lichius O, Muller A. Detection of HHV-8 sequences and antigens in a MALT lymphoma associated with Sjögren's syndrome. J Oral Pathol Med 2003;32:243–5.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>243</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB22"><titleInfo><title>Autoimmune Rev</title></titleInfo><note>Masaki Y, Sugai S. Lymphoproliferative disorders in Sjögren's syndrome. Autoimmune Rev 2004;3:175–82.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>175</start></extent></part></relatedItem><relatedItem type="references" displayLabel="BIB23"><titleInfo><title>Leuk Lymphoma</title></titleInfo><note>Kamel OW, van de Rijn M, Hanasono MM, Warnke RA. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma 1995;16:363–8.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>363</start></extent></part></relatedItem><identifier type="istex">CA2B6C7023C48C58447B90FC11749151572EE9B6</identifier><identifier type="ark">ark:/67375/HXZ-4GZSGV12-V</identifier><identifier type="DOI">10.1093/rheumatology/kei281</identifier><identifier type="local">kei281</identifier><accessCondition type="use and reproduction" contentType="copyright">© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource><recordOrigin>Converted from (version 1.2.0) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/HXZ-4GZSGV12-V/record.json</uri></json:item></metadata><covers><json:item><extension>tiff</extension><original>true</original><mimetype>image/tiff</mimetype><uri>https://api.istex.fr/document/CA2B6C7023C48C58447B90FC11749151572EE9B6/covers/tiff</uri></json:item></covers><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001014 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001014 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:CA2B6C7023C48C58447B90FC11749151572EE9B6
|texte= Incidence of cancer in a cohort of patients with primary Sjögren's syndrome
}}
| This area was generated with Dilib version V0.6.33. |  |